BRPI0910232A2 - formas de sais inibidores do mtor - Google Patents

formas de sais inibidores do mtor

Info

Publication number
BRPI0910232A2
BRPI0910232A2 BRPI0910232A BRPI0910232A BRPI0910232A2 BR PI0910232 A2 BRPI0910232 A2 BR PI0910232A2 BR PI0910232 A BRPI0910232 A BR PI0910232A BR PI0910232 A BRPI0910232 A BR PI0910232A BR PI0910232 A2 BRPI0910232 A2 BR PI0910232A2
Authority
BR
Brazil
Prior art keywords
salt forms
inhibitor salt
inhibitor
forms
salt
Prior art date
Application number
BRPI0910232A
Other languages
English (en)
Inventor
Arlindo L Castelhano
Gary C Visor
Josef A Rechka
Kristen Michelle Mulvihill
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of BRPI0910232A2 publication Critical patent/BRPI0910232A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0910232A 2008-03-19 2009-03-18 formas de sais inibidores do mtor BRPI0910232A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7006208P 2008-03-19 2008-03-19
PCT/US2009/037505 WO2009117482A1 (en) 2008-03-19 2009-03-18 Mtor inhibitor salt forms

Publications (1)

Publication Number Publication Date
BRPI0910232A2 true BRPI0910232A2 (pt) 2015-09-29

Family

ID=40597405

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910232A BRPI0910232A2 (pt) 2008-03-19 2009-03-18 formas de sais inibidores do mtor

Country Status (12)

Country Link
US (1) US8557814B2 (pt)
EP (1) EP2276763A1 (pt)
JP (1) JP2011515410A (pt)
KR (1) KR20110017845A (pt)
CN (1) CN101977912A (pt)
AU (1) AU2009225614A1 (pt)
BR (1) BRPI0910232A2 (pt)
CA (1) CA2716924A1 (pt)
EA (1) EA018144B1 (pt)
MX (1) MX2010010300A (pt)
WO (1) WO2009117482A1 (pt)
ZA (1) ZA201006641B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2365869T3 (es) * 2005-11-17 2011-10-11 OSI Pharmaceuticals, LLC COMPUESTOS BICÍCLICOS FUSIONADOS INHIBIDORES DE LA mTOR.
US20090274698A1 (en) * 2007-07-06 2009-11-05 Shripad Bhagwat Combination anti-cancer therapy
EP2276763A1 (en) 2008-03-19 2011-01-26 OSI Pharmaceuticals, Inc. Mtor inhibitor salt forms
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
NZ599830A (en) 2009-11-05 2014-08-29 Rhizen Pharmaceuticals Sa Novel kinase modulators
EP2544672A1 (en) 2010-03-09 2013-01-16 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
KR101548443B1 (ko) 2011-02-23 2015-08-28 화이자 인코포레이티드 신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진
PH12013502240B1 (en) 2011-05-04 2018-06-27 Rhizen Pharmaceuticals Sa Novel compounds as modulators of protein kinase
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
RS56494B1 (sr) 2012-07-04 2018-01-31 Rhizen Pharmaceuticals S A Selektivni inhibitori pi3k delta
EP3021849B1 (en) * 2013-07-16 2019-10-09 Dr. Reddy's Laboratories Ltd. Novel crystalline forms of pemetrexed tromethamine salts
KR102497273B1 (ko) 2014-03-06 2023-02-07 피티씨 테라퓨틱스, 인크. 1,2,4-옥사디아졸 벤조산의 약학 조성물 및 염
US9987241B2 (en) 2014-09-25 2018-06-05 The Board Of Regents Of The University Of Oklahoma Enzyme conjugate and prodrug cancer therapy
EP3209665B1 (en) 2014-10-22 2019-08-14 Bristol-Myers Squibb Company Substituted pyrrolotriazine amine compounds as pi3k inhibitors
ES2807785T3 (es) 2014-10-22 2021-02-24 Bristol Myers Squibb Co Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
KR102483020B1 (ko) 2016-03-28 2023-01-04 인사이트 코포레이션 Tam 저해제로서의 피롤로트리아진 화합물
US11446365B2 (en) 2017-08-09 2022-09-20 The Board Of Regents Of The University Of Oklahoma Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
FR3075794A1 (fr) 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
FR3075795A1 (fr) 2017-12-21 2019-06-28 Galderma Research & Development Nouveaux composes inhibiteurs de mtor
JOP20210147A1 (ar) * 2018-12-21 2023-01-30 Les Laboratoires Servier Sas صور بلورية وملح من مركب عضوي وتركيبات صيدلانية منه
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869485A (en) * 1994-09-29 1999-02-09 Novartis Finance Corp. Pyrrolo 2,3-d!pyrimidines and their use
TR199902301T2 (xx) * 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
US7863444B2 (en) * 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
US6383790B1 (en) * 1999-01-11 2002-05-07 Princeton University High affinity protein kinase inhibitors
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
AU2002333524A1 (en) * 2001-09-11 2003-03-24 Glaxosmithkline K.K. Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
UA83509C2 (en) * 2003-10-15 2008-07-25 Оси Фармасьютикалз, Инк. Imidazopyrazines as tyrosine kinase inhibitors
EP1687321A1 (en) * 2003-10-27 2006-08-09 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
CA2546192C (en) * 2003-11-17 2010-04-06 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
EP2168968B1 (en) * 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
TW200613306A (en) * 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
EP1831225A2 (en) * 2004-11-19 2007-09-12 The Regents of the University of California Anti-inflammatory pyrazolopyrimidines
ES2365869T3 (es) * 2005-11-17 2011-10-11 OSI Pharmaceuticals, LLC COMPUESTOS BICÍCLICOS FUSIONADOS INHIBIDORES DE LA mTOR.
AR057960A1 (es) * 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
ES2545907T3 (es) * 2005-12-29 2015-09-16 Abbvie Inc. Inhibidores de proteína quinasa
TW200738725A (en) * 2006-01-25 2007-10-16 Osi Pharm Inc Unsaturated mTOR inhibitors
EP1996193A2 (en) * 2006-03-13 2008-12-03 OSI Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
US20100273776A1 (en) 2006-03-29 2010-10-28 FOLDRx PHARMACEUTICALS, INC Inhibition of alpha-synuclein toxicity
WO2007114926A2 (en) * 2006-04-04 2007-10-11 The Regents Of The University Of California Kinase antagonists
DE102006016426A1 (de) 2006-04-07 2007-10-11 Merck Patent Gmbh Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren
US20090274698A1 (en) * 2007-07-06 2009-11-05 Shripad Bhagwat Combination anti-cancer therapy
EP2173338A1 (en) * 2007-07-06 2010-04-14 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy
MX2010004074A (es) * 2007-10-15 2010-07-02 Astrazeneca Ab Combinacion 059.
EP2276763A1 (en) 2008-03-19 2011-01-26 OSI Pharmaceuticals, Inc. Mtor inhibitor salt forms
BR112012000494A2 (pt) 2009-07-09 2015-09-15 Osi Pharmaceuticals Llc processo para 3-amino-5-oxo-4,5-di-hidro-[1,2,4]triazinas substituídas
EP2459191A1 (en) 2009-07-31 2012-06-06 OSI Pharmaceuticals, LLC Mtor inhibitor and angiogenesis inhibitor combination therapy

Also Published As

Publication number Publication date
KR20110017845A (ko) 2011-02-22
AU2009225614A1 (en) 2009-09-24
WO2009117482A8 (en) 2010-04-08
JP2011515410A (ja) 2011-05-19
WO2009117482A1 (en) 2009-09-24
CA2716924A1 (en) 2009-09-24
MX2010010300A (es) 2010-10-26
ZA201006641B (en) 2011-05-25
EP2276763A1 (en) 2011-01-26
US20110015197A1 (en) 2011-01-20
EA201071099A1 (ru) 2011-02-28
CN101977912A (zh) 2011-02-16
EA018144B1 (ru) 2013-05-30
US8557814B2 (en) 2013-10-15

Similar Documents

Publication Publication Date Title
BRPI0910232A2 (pt) formas de sais inibidores do mtor
CY2020023I1 (el) Αναστολεiς βητα-λακταμασων
FIC20200046I1 (fi) Alpelisibi tai sen suola
BRPI0922466A2 (pt) sais
BRPI0917808A2 (pt) inibidores de cmet
EP2305306A4 (en) NEURO INVASION INHIBITOR
BRPI0906764A2 (pt) Processos
EP2266026A4 (en) EFFICIENT DETERMINIST MULTIPLE PROCESSING
BRPI0911175A2 (pt) conjuntos de válvula
BRPI0821868A2 (pt) Grânulo
BRPI0908115A2 (pt) torneira
BRPI0924163A2 (pt) kit de limpeza de arma de fogo
BRPI0919591A2 (pt) válvula magnética
BRPI0918564A2 (pt) inibidores
BRPI0914781A2 (pt) Microbiocidas
BRPI0908513A2 (pt) válvula
BRPI0911625A2 (pt) Métodos
EP2317192A4 (en) MAGNETIC VALVE
FR2914943B1 (fr) Aube de soufflante
BRPI0821901A2 (pt) Válvula homogeneizadora
BRPI0909106A2 (pt) Método herbicida
BRPI0918966A2 (pt) inibidores de protease
BRPI0912564A2 (pt) inibidores de jnk
DE602007002163D1 (de) Weichspülmittel
IT1394067B1 (it) Valvola

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.